Physician profile
Alka Mallik
NPI 1215146386
$16,539.44
in general payments reported to CMS, 2019-2025
58 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,127 · 2020: $3,539 · 2021: $2,683 · 2022: $1,536 · 2023: $86.87 · 2024: $316 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.95 |
| Education | $174.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $6,552.31 | 2019-2022 | |
| Genentech USA, INC. | $1,154.20 | 2019-2022 | |
| Janssen Biotech, INC. | $842.09 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $819.02 | 2019-2022 | |
| Amgen INC. | $711.16 | 2019-2025 | Lumakras, Imdelltra (Amg757) |
| Genzyme Corporation | $553.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $501.55 | 2019-2022 | |
| Lilly USA, LLC | $456.38 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $393.80 | 2019-2025 | Enhertu, Imfinzi |
| Seagen INC. | $390.32 | 2019-2023 | Tukysa |
| Merck Sharp & Dohme LLC | $370.88 | 2019-2021 | |
| Pfizer INC. | $362.55 | 2019-2024 | |
| Incyte Corporation | $278.74 | 2019-2022 | |
| Puma Biotechnology, INC. | $207.09 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $197.45 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Mallik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.